And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is exceedingly modest. We plan to catch up on reading and napping, not always in that order, and, of course, hanging out with Mrs. Pharmalot and the short person. And what about you? This may be an opportunity to catch up with someone special, plan a needed getaway, or catch up on the latest national drama. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon …
A number of positions at the Food and Drug Administration, notably in the Office of New Drugs, will likely be exempt from President Trump’s federal hiring freeze, according to Regulatory Focus, citing an internal memo from the Department of Health and Human Services. But during the 90-day freeze, appointments to advisory committees “will only be considered for positions for those committees that are legally mandated.”
A group of academic researchers is demanding an end to cancer drugs that cost more than $100,000 a year and put forth a new model for low-cost drug development that would take advantage of recent medical advances, Reuters writes. One suggestion: Academic groups should consider working with smaller companies that commit to capping prices, low-cost generic drug makers, or nonprofit organizations. Their proposals were published in Cell.
About the Author Reprints
